The emerging global epidemic of paediatric inflammatory bowel disease - causes and consequences

Journal of Internal Medicine

Volumn 279, Issue 3, 2016, Pages 241-258

  Malmborg, Petter ^a   Hildebrand, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Crohn's disease; Epidemiology; Growth; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL STRAIN; CHILD; CHILDHOOD DISEASE; COMMENSAL; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DOWN REGULATION; ENTERIC FEEDING; ENVIRONMENTAL FACTOR; EPIDEMIC; EXPOSURE; FOLLOW UP; FOOD INTAKE; GASTROSTOMY; GROWTH DISORDER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE FLORA; MICROBIAL COLONIZATION; NUTRITIONAL SUPPORT; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; CLASSIFICATION; INFLAMMATORY BOWEL DISEASES; RISK FACTOR;

CHILD; EPIDEMICS; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS;

EID: 84958928616     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12413     Document Type: Article

References (173)

1. Hildebrand H, Finkel Y, Grahnquist L, Lindholm J, Ekbom A, Askling J. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001. Gut 2003; 52: 1432-4.
2. Malmborg P, Grahnquist L, Lindholm J, Montgomery S, Hildebrand H. Increasing incidence of paediatric inflammatory bowel disease in northern Stockholm County, 2002-2007. J Pediatr Gastroenterol Nutr 2013; 57: 29-34.
3. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17: 423-39.
4. Sjoberg D, Holmstrom T, Larsson M et al. Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005-2009 - results from the IBD cohort of the Uppsala Region (ICURE). J Crohns Colitis 2013; 7: e351-7.
5. Lehtinen P, Ashorn M, Iltanen S et al. Incidence trends of pediatric inflammatory bowel disease in Finland, 1987-2003, a nationwide study. Inflamm Bowel Dis 2011; 17: 1778-83.
6. Benchimol EI, Guttmann A, Griffiths AM et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut 2009; 58: 1490-7.
7. Pundziute-Lycka A, Dahlquist G, Nystrom L et al. The incidence of Type I diabetes has not increased but shifted to a younger age at diagnosis in the 0-34 years group in Sweden 1983-1998. Diabetologia 2002; 45: 783-91.
8. Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008; 371: 1777-82.
9. Gopinath S, Ortqvist E, Norgren S, Green A, Sanjeevi CB. Variations in incidence of type 1 diabetes in different municipalities of Stockholm. Ann N Y Acad Sci 2008; 1150: 200-7.
10. Sjoberg D, Holmstrom T, Larsson M et al. Incidence and clinical course of Crohn's disease during the first year - Results from the IBD Cohort of the Uppsala Region (ICURE) of Sweden 2005-2009. J Crohns Colitis 2014; 8: 215-22.
11. Grieci T, Butter A. The incidence of inflammatory bowel disease in the pediatric population of Southwestern Ontario. J Pediatr Surg 2009; 44: 977-80.
12. Turunen P, Kolho KL, Auvinen A, Iltanen S, Huhtala H, Ashorn M. Incidence of inflammatory bowel disease in Finnish children, 1987-2003. Inflamm Bowel Dis 2006; 12: 677-83.
13. Jakobsen C, Wewer V, Urne F et al. Incidence of ulcerative colitis and Crohn's disease in Danish children: still rising or levelling out? J Crohns Colitis 2008; 2: 152-7.
14. Perminow G, Brackmann S, Lyckander LG et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005-07, showing increased incidence in Crohn's disease. Scand J Gastroenterol 2009; 44: 446-56.
15. Bousvaros A, Antonioli DA, Colletti RB et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatr Gastroenterol Nutr 2007; 44: 653-74.
16. Henriksen M, Jahnsen J, Lygren I et al. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study). Scand J Gastroenterol 2006; 41: 1037-43.
17. Malaty HM, Mehta S, Abraham B, Garnett EA, Ferry GD. The natural course of inflammatory bowel disease-indeterminate from childhood to adulthood: within a 25 year period. Clin Exp Gastroenterol 2013; 6: 115-21.
18. Halfvarson J, Jess T, Bodin L et al. Longitudinal concordance for clinical characteristics in a Swedish-Danish twin population with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1536-44.
19. Halfvarson J, Jess T, Magnuson A et al. Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. Inflamm Bowel Dis 2006; 12: 925-33.
20. Begue B, Verdier J, Rieux-Laucat F et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol 2011; 106: 1544-55.
21. Abramson O, Durant M, Mow W et al. Incidence, prevalence, and time trends of pediatric inflammatory bowel disease in Northern California, 1996 to 2006. J Pediatr 2010; 157: 233-9.e1.
22. Montgomery SM, Morris DL, Pounder RE, Wakefield AJ. Asian ethnic origin and the risk of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999; 11: 543-6.
23. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988; 29: 990-6.
24. Cornish JA, Tan E, Simillis C, Clark SK, Teare J, Tekkis PP. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008; 103: 2394-400.
25. Ekbom A, Adami HO, Helmick CG, Jonzon A, Zack MM. Perinatal risk factors for inflammatory bowel disease: a case-control study. Am J Epidemiol 1990; 132: 1111-9.
26. Wurzelmann JI, Lyles CM, Sandler RS. Childhood infections and the risk of inflammatory bowel disease. Dig Dis Sci 1994; 39: 555-60.
27. Barclay AR, Russell RK, Wilson ML, Gilmour WH, Satsangi J, Wilson DC. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr 2009; 155: 421-6.
28. Soderhjelm L, Zetterstrom R. Trends in infant feeding in Sweden during the 20th century. Acta Paediatr Scand Suppl 1990; 365: 5-6.
29. Rutgeerts P, Goboes K, Peeters M et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338: 771-4.
30. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
31. Parkes M, Barrett JC, Prescott NJ et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. New IBD genetics: common pathways with other diseases. Nat Genet 2007; 39: 830-2.
32. Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 2005; 206: 277-95.
33. De Filippo C, Cavalieri D, Di Paola M et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A 2010; 107: 14691-6.
34. Wold AE, Adlerberth I. Pathological consequences of commensalism. In: Nataro JP, Blaser MJ, Cunningham-Rundles S, eds. Persistent Bacterial Infections. Washington, DC, USA: ASM Press, 2000; 115-44.
35. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9: 313-23.
36. Ellis-Pegler RB, Crabtree C, Lambert HP. The faecal flora of children in the United Kingdom. J Hyg (Lond). 1975; 75: 135-42.
37. Adlerberth I, Lindberg E, Aberg N et al. Reduced enterobacterial and increased staphylococcal colonization of the infantile bowel: an effect of hygienic lifestyle? Pediatr Res 2006; 59: 96-101.
38. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008; 105: 16731-6.
39. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003; 361: 1869-71.
40. Favier CF, Vaughan EE, De Vos WM, Akkermans AD. Molecular monitoring of succession of bacterial communities in human neonates. Appl Environ Microbiol 2002; 68: 219-26.
41. Bedford Russell AR, Murch SH. Could peripartum antibiotics have delayed health consequences for the infant? BJOG 2006; 113: 758-65.
42. Salminen S, Gibson GR, McCartney AL, Isolauri E. Influence of mode of delivery on gut microbiota composition in seven year old children. Gut 2004; 53: 1388-9.
43. Hildebrand H, Malmborg P, Askling J, Ekbom A, Montgomery SM. Early-life exposures associated with antibiotic use and risk of subsequent Crohn's disease. Scand J Gastroenterol 2008; 43: 961-6.
44. Malmborg P, Bahmanyar S, Grahnquist L, Hildebrand H, Montgomery S. Cesarean section and the risk of pediatric Crohn's disease. Inflamm Bowel Dis 2011; 27: 21741.
45. Virta L, Auvinen A, Helenius H, Huovinen P, Kolho KL. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease-a nationwide, register-based finnish case-control study. Am J Epidemiol 2012; 175: 775-84.
46. Hviid A, Svanstrom H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut 2011; 60: 49-54.
47. Molstad S, Erntell M, Hanberger H et al. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect Dis. 2008; 8: 125-32.
48. Hildebrand H, Fredrikzon B, Holmquist L, Kristiansson B, Lindquist B. Chronic inflammatory bowel disease in children and adolescents in Sweden. J Pediatr Gastroenterol Nutr 1991; 13: 293-7.
49. Lindberg E, Lindquist B, Holmquist L, Hildebrand H. Inflammatory bowel disease in children and adolescents in Sweden, 1984-1995. J Pediatr Gastroenterol Nutr 2000; 30: 259-64.
50. Martin-de-Carpi J, Rodriguez A, Ramos E, Jimenez S, Martinez-Gomez MJ, Medina E. Increasing incidence of pediatric inflammatory bowel disease in Spain (1996-2009): the SPIRIT Registry. Inflamm Bowel Dis 2013; 19: 73-80.
51. Molstad S, Lundborg CS, Karlsson AK, Cars O. Antibiotic prescription rates vary markedly between 13 European countries. Scand J Infect Dis 2002; 34: 366-71.
52. Bager P, Simonsen J, Nielsen NM, Frisch M. Cesarean section and offspring's risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis 2012; 18: 857-62.
53. Perminow G, Frigessi A, Rydning A, Nakstad B, Vatn MH. Incidence and clinical presentation of IBD in children: comparison between prospective and retrospective data in a selected Norwegian population. Scand J Gastroenterol 2006; 41: 1433-9.
54. IBD Working Group of ESPGHAN. Inflammatory bowel disease in children and adolescents recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1-7.
55. Levine A, Koletzko S, Turner D et al. The ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2013; 13: 13.
56. Solberg IC, Lygren I, Jahnsen J et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44: 431-40.
57. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3-11.
58. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323: 1228-33.
59. Bernstein CN, Ng SC, Lakatos PL, Moum B, Loftus EV Jr. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis 2013; 19: 2001-10.
60. Solberg IC, Vatn MH, Hoie O et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430-8.
61. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706.
62. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50.
63. Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1994; 18: 165-73.
64. Stjernman H, Tysk C, Almer S, Strom M, Hjortswang H. Unfavourable outcome for women in a study of health-related quality of life, social factors and work disability in Crohn's disease. Eur J Gastroenterol Hepatol 2011; 23: 671-9.
65. Canavan C, Abrams KR, Hawthorne B, Mayberry JF. Long-term prognosis in Crohn's disease: an epidemiological study of patients diagnosed more than 20 years ago in Cardiff. Aliment Pharmacol Ther 2007; 25: 59-65.
66. Wolters FL, Russel MG, Sijbrandij J et al. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 2006; 55: 510-8.
67. Hovde O, Kempski-Monstad I, Smastuen MC et al. Mortality and causes of death in Crohn's disease: results from 20 years of follow-up in the IBSEN study. Gut 2013; 6: 6.
68. Manninen P, Karvonen AL, Huhtala H et al. Mortality in ulcerative colitis and Crohn's disease. A population-based study in Finland. J Crohns Colitis 2012; 6: 524-8.
69. Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology 1975; 68(4 Pt 1): 627-35.
70. Sachar DB, Andrews HA, Farmer RG. Proposed classification of patient subgroups in Crohn's disease. Gastroenterol Int 1992; 5: 141-54.
71. Gasche C, Scholmerich J, Brynskov J et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15.
72. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
73. Levine A, Griffiths A, Markowitz J et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17: 1314-21.
74. Heyman MB, Kirschner BS, Gold BD et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005; 146: 35-40.
75. Gale G, Ostman S, Rekabdar E et al. Characterisation of a Swedish cohort with orofacial granulomatosis with or without Crohn's disease. Oral Dis 2015; 21: e98-104.
76. Crohn BB, Yunich AM. Ileojejunitis. Ann Surg 1941; 113: 371-80.
77. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16: 373-80.
78. Kirschner BS. Permanent growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16: 368-9.
79. Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn's disease. Gut 1993; 34: 939-43.
80. Wine E, Reif SS, Leshinsky-Silver E et al. Pediatric Crohn's disease and growth retardation: the role of genotype, phenotype, and disease severity. Pediatrics 2004; 114: 1281-6.
81. Shamir R, Phillip M, Levine A. Growth retardation in pediatric Crohn's disease: pathogenesis and interventions. Inflamm Bowel Dis 2007; 13: 620-8.
82. Kirschner BS, Klich JR, Kalman SS, deFavaro MV, Rosenberg IH. Reversal of growth retardation in Crohn's disease with therapy emphasizing oral nutritional restitution. Gastroenterology 1981; 80: 10-5.
83. Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1993; 17: 75-81.
84. Aiges H, Markowitz J, Rosa J, Daum F. Home nocturnal supplemental nasogastric feedings in growth-retarded adolescents with Crohn's disease. Gastroenterology 1989; 97: 905-10.
85. Beattie RM, Schiffrin EJ, Donnet-Hughes A et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Aliment Pharmacol Ther 1994; 8: 609-15.
86. Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000; 31: 8-15.
87. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007; 13: 424-30.
88. Alperstein G, Daum F, Fisher SE et al. Linear growth following surgery in children and adolescents with Crohn's disease: relationship to pubertal status. J Pediatr Surg 1985; 20: 129-33.
89. Van Limbergen J, Russell RK, Drummond HE et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135: 1114-22.
90. Jakobsen C, Bartek J, Wewer V et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease - a population-based study. Aliment Pharmacol Ther 2011; 34: 1217-24.
91. Lovasz BD, Lakatos L, Horvath A et al. Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort. World J Gastroenterol 2013; 19: 2217-26.
92. Israeli E, Ryan JD, Shafer LA, Bernstein CN. Younger age at diagnosis is associated with panenteric, but not more aggressive, Crohn's disease. Clin Gastroenterol Hepatol 2014; 12: 72-9.e1.
93. Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World J Gastroenterol 2006; 12: 75-81.
94. Vernier-Massouille G, Balde M, Salleron J et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135: 1106-13.
95. Polito JM 2nd, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996; 111: 580-6.
96. Griffiths A, Koletzko S, Sylvester F, Marcon M, Sherman P. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease. J Pediatr Gastroenterol Nutr 1993; 17: 186-92.
97. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902.
98. Svartz N. The treatment of ulcerative colitis. Gastroenterologia 1956; 86: 683-8.
99. Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964; 5: 437-42.
100. Turner D, Levine A, Escher JC et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012; 55: 340-61.
101. Ruemmele FM, Veres G, Kolho KL et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014; 8: 1179-207.
102. Turner D, Travis SP, Griffiths AM et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011; 106: 574-88.
103. Israel DM, Hassall E. Prolonged use of gastrostomy for enteral hyperalimentation in children with Crohn's disease. Am J Gastroenterol 1995; 90: 1084-8.
104. O'Morain C, Segal AW, Levi AJ. Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. Br Med J (Clin Res Ed) 1984; 288: 1859-62.
105. Sanderson IR, Udeen S, Davies PS, Savage MO, Walker-Smith JA. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987; 62: 123-7.
106. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007; (1): CD000542.
107. Lionetti P, Callegari ML, Ferrari S et al. Enteral nutrition and microflora in pediatric Crohn's disease. JPEN J Parenter Enteral Nutr 2005; 29(4 Suppl): S173-5; discussion S5-8.
108. Bannerjee K, Camacho-Hubner C, Babinska K et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 2004; 38: 270-5.
109. Fell JM, Paintin M, Arnaud-Battandier F et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14: 281-9.
110. Landi B, Anh TN, Cortot A et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102: 1647-53.
111. Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F et al. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther 2004; 20: 167-72.
112. Wilschanski M, Sherman P, Pencharz P, Davis L, Corey M, Griffiths A. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996; 38: 543-8.
113. Evans CM, Kirk JM, Savage MO, Walker-Smith JA. Growth after gut resection for Crohn's disease. Arch Dis Child 1991; 66: 370.
114. Nicholls S, Vieira MC, Majrowski WH, Shand WS, Savage MO, Walker-Smith JA. Linear growth after colectomy for ulcerative colitis in childhood. J Pediatr Gastroenterol Nutr 1995; 21: 82-6.
115. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
116. Watts JM, De Dombal FT, Watkinson G, Goligher JC. Long-term prognosis of ulcerative colitis. Br Med J 1966; 1: 1447-53.
117. Gustavsson A, Jarnerot G, Hertervig E et al. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010; 32: 984-9.
118. Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25: 3-12.
119. Uhlen S, Belbouab R, Narebski K et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis 2006; 12: 1053-7.
120. Weiss B, Lerner A, Shapiro R et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr 2009; 48: 526-30.
121. Chande N, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2014; (8): CD006618.
122. IBD-vårdprogramgruppen. Vårdprogram inflammatorisk tarmsjukdom hos barn och ungdomar: Svenska föreningen för pediatrisk gastroenterologi, hepatologi och nutrition. Svenska barnläkarföreningen; 2002 [updated 2013-05-06].
123. Askling J, Baecklund E, Granath F et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009; 68: 648-53.
124. Derkx B, Taminiau J, Radema S et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993; 342: 173-4.
125. Kotlyar DS, Lewis JD, Beaugerie L et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 2015; 13: 847-58.
126. Ashworth LA, Billett A, Mitchell P, Nuti F, Siegel C, Bousvaros A. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis 2012; 18: 838-43.
127. Osterman MT, Sandborn WJ, Colombel JF et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology 2014; 146: 941-9.
128. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013; 108: 99-105.
129. Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol 2004; 18: 509-23.
130. Gower-Rousseau C, Dauchet L, Vernier-Massouille G et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol 2009; 104: 2080-8.
131. Markowitz J, Hyams J, Mack D et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1124-9.
132. Hyams J, Markowitz J, Lerer T et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006; 4: 1118-23.
133. Pigneur B, Seksik P, Viola S et al. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis 2010; 16: 953-61.
134. Jess T, Riis L, Vind I et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007; 13: 481-9.
135. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-41.
136. Malmborg P, Grahnquist L, Idestrom M et al. Presentation and progression of childhood-onset inflammatory bowel disease in northern Stockholm County. Inflamm Bowel Dis 2015; 21: 1098-108.
137. Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008; 103: 3082-93.
138. Rungoe C, Langholz E, Andersson M et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 2014; 63: 1607-16.
139. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol 2013; 29: 397-404.
140. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
141. Rantalaiho V, Korpela M, Laasonen L et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010; 12: R122.
142. Felson DT, Smolen JS, Wells G et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70: 404-13.
143. D'Haens G, Ferrante M, Vermeire S et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2218-24.
144. Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep 2013; 15: 315.
145. Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22.
146. Baert F, Moortgat L, Van Assche G et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-8; quiz e10-1.
147. Colombel JF, Rutgeerts PJ, Sandborn WJ et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12: 414-22.
148. Koevoets R, Dirven L, Klarenbeek NB et al. Insights in the relationship of joint space narrowing versus erosive joint damage and physical functioning of patients with RA. Ann Rheum Dis 2013; 72: 870-4.
149. Peyrin-Biroulet L, Cieza A, Sandborn WJ et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012; 61: 241-7.
150. Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009; 48: 386-8.
151. Savoye G, Salleron J, Gower-Rousseau C et al. Clinical predictors at diagnosis of disabling pediatric Crohn's disease. Inflamm Bowel Dis 2012; 18: 2072-8.
152. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948-54.
153. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 97: 947-53.
154. Huttenhower C, Gevers D, Knight R et al. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486: 207-14.
155. Nwosu FC, Thorkildsen LT, Avershina E et al. Age-dependent fecal bacterial correlation to inflammatory bowel disease for newly diagnosed untreated children. Gastroenterol Res Pract. 2013; 2013: 302398.
156. Sinagra E, Tomasello G, Cappello F et al. Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights. J Biol Regul Homeost Agents 2013; 27: 919-33.
157. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36: 503-16.
158. Kruger M, Shehata AA, Schrodl W, Rodloff A. Glyphosate suppresses the antagonistic effect of Enterococcus spp. on Clostridium botulinum. Anaerobe 2013; 20: 74-8.
159. Chassaing B, Koren O, Goodrich JK et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015; 519: 92-6.
160. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-73; quiz 1165-6.
161. Hyams J, Damaraju L, Blank M et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012; 10: 391-9.e1.
162. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-28.
163. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-38.
164. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
165. Krivan G, Szabo D, Kallay K et al. Successful autologous haematopoietic stem cell transplantation in severe, therapy-resistant childhood Crohn's disease. Report on the first case in Hungary. Orv Hetil 2014; 155: 789-92.
166. Hawkey CJ. Stem cells as treatment in inflammatory bowel disease. Dig Dis 2012; 30(Suppl 3): 134-9.
167. Tyndall A, Fassas A, Passweg J et al. Autologous haematopoietic stem cell transplants for autoimmune disease-feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease. Bone Marrow Transplant 1999; 24: 729-34.
168. Duijvestein M, Vos AC, Roelofs H et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010; 59: 1662-9.
169. Garcia-Olmo D, Herreros D, Pascual I et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009; 52: 79-86.
170. Solberg IC, Cvancarova M, Vatn MH, Moum B. Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's disease (the IBSEN study). Inflamm Bowel Dis 2014; 20: 60-8.
171. Molander P, af Bjorkesten CG, Mustonen H et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents. Inflamm Bowel Dis 2012; 18: 2011-7.
172. Panaccione R, Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ. Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis 2013; 19: 1645-53.
173. Malmborg P. Aetiology and Prognosis of Paediatric Inflammatory Bowel Disease [Doctoral thesis]. Stockholm: Karolinska Institutet, 2014.